Viridian Therapeutics, Inc.\DE - 10-Q Filing

Viridian Therapeutics reports Q3 2026 financial results including details on convertible senior notes and debt covenants.

SEC EDGAR ·

Tickers: $VRDN

Read the full article at SEC EDGAR

More Regulatory news